Episode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma
Blood Cancer Talks
00:00
Cerebellar Toxicity in GPRC 5D CAR-T
Cerebellar toxicity was seen in two patients receiving the 450 million dose. It's possible that they're able to find a dose where you get an efficacy and maybe a lower risk of this cerebellum toxicity. So, I don't know if it's going to be a major barrier. I think we'll have to wait and see as we treat more numbers. My hope, though, is that this is something that's very uncommon and won't be a barrier.
Transcript
Play full episode
